Literature DB >> 16778211

Apoptosis induction by retinoids in eosinophilic leukemia cells: implication of retinoic acid receptor-alpha signaling in all-trans-retinoic acid hypersensitivity.

Carine Robert1, Laurent Delva, Nicole Balitrand, Sarolta Nahajevszky, Tamàs Masszi, Christine Chomienne, Béla Papp.   

Abstract

Hypereosinophilic syndrome (HES) has recently been recognized as a clonal leukemic lesion, which is due to a specific oncogenic event that generates hyperactive platelet-derived growth factor receptor-alpha-derived tyrosine kinase fusion proteins. In the present work, the effect of retinoids on the leukemic hypereosinophilia-derived EoL-1 cell line and on primary HES-derived cells has been investigated. We show that all-trans-retinoic acid (ATRA) inhibits eosinophil colony formation of HES-derived bone marrow cells and is a powerful inducer of apoptosis of the EoL-1 cell line. Apoptosis was shown in the nanomolar concentration range by phosphatidylserine externalization, proapoptotic shift of the Bcl-2/Bak ratio, drop in mitochondrial membrane potential, activation of caspases, and cellular morphology. Unlike in other ATRA-sensitive myeloid leukemia models, apoptosis was rapid and was not preceded by terminal cell differentiation. Use of isoform-selective synthetic retinoids indicated that retinoic acid receptor-alpha-dependent signaling is sufficient to induce apoptosis of EoL-1 cells. Our work shows that the scope of ATRA-induced apoptosis of malignancies may be wider within the myeloid lineage than thought previously, that the EoL-1 cell line constitutes a new and unique model for the study of ATRA-induced cell death, and that ATRA may have potential for the management of clonal HES.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778211     DOI: 10.1158/0008-5472.CAN-06-0078

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Proteomic and Phosphoproteomic Changes Induced by Prolonged Activation of Human Eosinophils with IL-3.

Authors:  Stephane Esnault; Alexander S Hebert; Nizar N Jarjour; Joshua J Coon; Deane F Mosher
Journal:  J Proteome Res       Date:  2018-05-04       Impact factor: 4.466

2.  Epstein-Barr virus latent membrane protein 1 increases calcium influx through store-operated channels in B lymphoid cells.

Authors:  Olivier Dellis; Atousa Arbabian; Béla Papp; Martin Rowe; Irène Joab; Christine Chomienne
Journal:  J Biol Chem       Date:  2011-03-30       Impact factor: 5.157

Review 3.  Mitochondrial metabolism inhibitors for cancer therapy.

Authors:  Emma E Ramsay; Philip J Hogg; Pierre J Dilda
Journal:  Pharm Res       Date:  2011-09-15       Impact factor: 4.200

4.  Tazarotene induces apoptosis in human basal cell carcinoma via activation of caspase-8/t-Bid and the reactive oxygen species-dependent mitochondrial pathway.

Authors:  Chieh-Shan Wu; Gwo-Shing Chen; Ping-Yi Lin; I-Hong Pan; San-Tang Wang; Sheng Hao Lin; Hsin-Su Yu; Chi-Chen Lin
Journal:  DNA Cell Biol       Date:  2014-06-13       Impact factor: 3.311

5.  Therapeutic effects of all trans-retinoic acid combined with transarterial chemoembolization on Walker-256 hepatoma in rats.

Authors:  Jianlin Fang; Chuansheng Zheng; Hongfang Tao; Hui Zhao; Jianzhuang Ren; Gansheng Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-02-14

6.  Retinoid differentiation therapy for common types of acute myeloid leukemia.

Authors:  Geoffrey Brown; Philip Hughes
Journal:  Leuk Res Treatment       Date:  2012-06-12

7.  Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent.

Authors:  Pengli Bu; Yu-Jui Yvonne Wan
Journal:  BMC Cancer       Date:  2007-12-31       Impact factor: 4.430

8.  DNMT3A mutants provide proliferating advantage with augmentation of self-renewal activity in the pathogenesis of AML in KMT2A-PTD-positive leukemic cells.

Authors:  Rabindranath Bera; Ming-Chun Chiu; Ying-Jung Huang; Gang Huang; Yun-Shien Lee; Lee-Yung Shih
Journal:  Oncogenesis       Date:  2020-02-03       Impact factor: 6.524

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.